26 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2028. from the record
Of the 7 now held by other companies, 2 name Hopitaux Universitaires de Geneve as their current owner, and 5 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Apr 2028
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2030 · High confidence
Also notable
Ends Sep 2033 · High confidence
Also notable
Ends Jul 2029 · High confidence
Secure Item Identification and Authentication System and Method Based on Unclonable Features
US 8,705,873
Cited by 83 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Nucleic Acids for Down-Regulation of Gene Expression
US 9,556,433
Cited by 32 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Diagnostic Method for Brain Damage-Related Disorders
US 9,028,825
Cited by 30 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Formerly held, still cited
Notable
Ends Aug 2031 · High confidence
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2031.
now held by Hopitaux Universitaires de Geneve
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Method and Device for Optics Based Quantum Random Number Generation (US 10,331,412) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Feb 11, 2027The maintenance fee for Methods for the Treatment of Insulin Resistance (US 9,101,569) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
- 2 fees due May 17 to 28, 2027 · next May 17
- 1 fee due Sep 5, 2027The maintenance fee for BETA-2-Glycoprotein 1 Derived Peptide and Use Thereof for Treating Antiphospholipid Syndrome (US 11,919,939) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 19, 2026
- 1 term has ended since Aug 19, 2026
What they patent
The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method and Device for Optics Based Quantum Random Number Generation | 2 in force | to Dec 2035 |
| Adenosine 2A Receptor Modulators for Use in the Treatment of Cancer | 1 in force | to May 2043 |
| FlmG-Dependent Soluble Protein O-Glycosylation Systems In Bacteria | 1 in force | to Apr 2043 |
| Prospective Markers in Traumatic Brain Injury (TBI) | 1 in force | to Sep 2042 |
| Antimicrobial Tailored Chitosan | 1 in force | to Jun 2042 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,790,379 | Mapping of Proteins Along Chromatin by Chromatin Cleavage In force · High confidence | In force | High confidence | |
| US 7,644,281 | Character and Vector Graphics Watermark for Structured Electronic Documents Security In force · High confidence | In force | High confidence | |
| US 9,028,825 | Diagnostic Method for Brain Damage-Related Disorders In force · High confidence | In force | High confidence | |
| US 8,705,873 | Secure Item Identification and Authentication System and Method Based on Unclonable Features In force · High confidence | In force | High confidence | |
| US 9,101,569 | Methods for the Treatment of Insulin Resistance In force · High confidence | In force | High confidence | |
| US 9,187,534 | Multi-Epitopic Vaccine In force · High confidence | In force | High confidence | |
| US 9,657,064 | Cell Penetrating Peptides In force · High confidence | In force | High confidence | |
| US 9,556,433 | Nucleic Acids for Down-Regulation of Gene Expression held by Universite de Geneve and University of Pretoria In force · High confidence | In force | High confidence | |
| US 9,794,067 | Method for Active Content Fingerprinting In force · High confidence | In force | High confidence | |
| US 9,448,167 | Measurement Device and Method for Detection of Airborne Particles In force · High confidence | In force | High confidence |
Also on record, not counted in the 26: 7 patents in force now held by others · 37 patents ended · 16 applications pending · 40 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.